Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (41-50 of 192) with videos related to

Pageof 20
Sort By:
Investigational New Drugs|June 20, 2020
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumabMotohiro Tamiya, Kei Kunimasa, Kazumi Nishino, et al.
Anticancer Research|December 27, 2011
Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignanciesMotohiro Tamiya, Hanako Kuhara, Tomonori Hirashima, et al.
Anticancer Research|January 31, 2012
A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesotheliomaMasayoshi Higashiguchi, Hidekazu Suzuki, Tomonori Hirashima, et al.
Medical Oncology (Northwood, London, England)|July 16, 2010
Prognosis of small-cell lung cancer since the introduction of amrubicinHidekazu Suzuki, Tomonori Hirashima, Masashi Kobayashi, et al.
BMC Cancer|October 5, 2018
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)Motoko Tachihara, Shunichi Negoro, Takako Inoue, et al.
Lung Cancer (Amsterdam, Netherlands)|April 14, 2023
Clinical application of the AMOY 9-in-1 panel to lung cancer patientsKei Kunimasa, Shingo Matsumoto, Takahisa Kawamura, et al.
Internal Medicine (Tokyo, Japan)|March 18, 2016
Effective Management of Persistent Pneumothorax Using a Thopaz® Digital Drainage System Combined with an Endobronchial Watanabe SpigotTakayuki Shiroyama, Norio Okamoto, Motohiro Tamiya, et al.
BMC Cancer|January 3, 2018
Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancerToshihiko Kaneda, Hiroshige Yoshioka, Motohiro Tamiya, et al.
Lung Cancer Management|April 30, 2020
Switching from first or second generation EGFR-TKI to osimertinib in <i>EGFR</i> mutation-positive NSCLCFumio Imamura, Takako Inoue, Kei Kunimasa, et al.
Asia-Pacific Journal of Clinical Oncology|May 10, 2014
Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failureHidekazu Suzuki, Tomonori Hirashima, Norio Okamoto, et al.
Pageof 20

Showing results (41-50 of 192) with videos related to

Sort By:
Pageof 20
Investigational New Drugs|June 20, 2020
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumabMotohiro Tamiya, Kei Kunimasa, Kazumi Nishino, et al.
Anticancer Research|December 27, 2011
Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignanciesMotohiro Tamiya, Hanako Kuhara, Tomonori Hirashima, et al.
Anticancer Research|January 31, 2012
A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesotheliomaMasayoshi Higashiguchi, Hidekazu Suzuki, Tomonori Hirashima, et al.
Medical Oncology (Northwood, London, England)|July 16, 2010
Prognosis of small-cell lung cancer since the introduction of amrubicinHidekazu Suzuki, Tomonori Hirashima, Masashi Kobayashi, et al.
BMC Cancer|October 5, 2018
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)Motoko Tachihara, Shunichi Negoro, Takako Inoue, et al.
Lung Cancer (Amsterdam, Netherlands)|April 14, 2023
Clinical application of the AMOY 9-in-1 panel to lung cancer patientsKei Kunimasa, Shingo Matsumoto, Takahisa Kawamura, et al.
Internal Medicine (Tokyo, Japan)|March 18, 2016
Effective Management of Persistent Pneumothorax Using a Thopaz® Digital Drainage System Combined with an Endobronchial Watanabe SpigotTakayuki Shiroyama, Norio Okamoto, Motohiro Tamiya, et al.
BMC Cancer|January 3, 2018
Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancerToshihiko Kaneda, Hiroshige Yoshioka, Motohiro Tamiya, et al.
Lung Cancer Management|April 30, 2020
Switching from first or second generation EGFR-TKI to osimertinib in <i>EGFR</i> mutation-positive NSCLCFumio Imamura, Takako Inoue, Kei Kunimasa, et al.
Asia-Pacific Journal of Clinical Oncology|May 10, 2014
Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failureHidekazu Suzuki, Tomonori Hirashima, Norio Okamoto, et al.
Pageof 20